There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on KalVista Pharmaceuticals (KALV – Research Report) and Allakos (ALLK – Research Report) with bullish sentiments.
KalVista Pharmaceuticals (KALV)
In a report released today, Serge Belanger from Needham maintained a Buy rating on KalVista Pharmaceuticals, with a price target of $35.00. The company’s shares closed last Monday at $13.70.
According to TipRanks.com, Belanger is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for KalVista Pharmaceuticals with a $30.75 average price target, representing a 134.7% upside. In a report issued on February 13, Stifel Nicolaus also maintained a Buy rating on the stock with a $39.00 price target.
See today’s best-performing stocks on TipRanks >>
Allakos (ALLK)
JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Allakos today and set a price target of $3.00. The company’s shares closed last Monday at $1.47, close to its 52-week low of $1.00.
According to TipRanks.com, Wolleben is a 5-star analyst with an average return of
Currently, the analyst consensus on Allakos is a Hold with an average price target of $2.10.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on KALV:
